Research and Markets: Erythropoietin, Current Market Dynamics & Future Outlook.
DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c9341) has announced the addition of Erythropoietin erythropoietin /eryth·ro·poi·e·tin/ (-poi´e-tin) a glycoprotein hormone secreted by the kidney in the adult and by the liver in the fetus, which acts on stem cells of the bone marrow to stimulate red blood cell production , Current Market Dynamics & Future Outlook to their offering.
By the end of 2003 the world market for erythropoietin was valued at $10.3 billion, a growth of 14% over 2002. The market has been growing at an average annual growth rate of 21% over the previous 5 years. The market for Erythropoietin is very lucrative. Marketing costs are low due to the well-defined patient population and distribution costs distribution costs distribute npl → Vertriebskosten pl are low due to the limited distribution outlets. Since the market is a virtual oligopoly oligopoly: see monopoly.
Market situation in which producers are so few that the actions of each of them have an impact on price and on competitors. Each producer must consider the effect of a price change on the others. barriers to entry are high thus insuring high profitability. Although patent fortification fortification, system of defense structures for protection from enemy attacks. Fortification developed along two general lines: permanent sites built in peacetime, and emplacements and obstacles hastily constructed in the field in time of war. in the US limits competition in this market opportunities are still available for new comers. Epoetin Alfa e·po·e·tin al·fa
A recombinant preparation of human erythropoietin used to treat some forms of anemia.
Epogen, Eprex (CA) (UK), Procrit
Pharmacologic class: key patents starts to expire in the US in October 2004 and in Europe in December 2004.
Already generic products have been developed and is currently being marketed in Asia, Latin America Latin America, the Spanish-speaking, Portuguese-speaking, and French-speaking countries (except Canada) of North America, South America, Central America, and the West Indies. and Eastern Europe. With such a huge market at stakes both large multinationals such as Novartis's Sandoz biogenerics division and large generics producers such as Ratiopharm of Germany are eyeing the market. Many new and emerging dedicated biogenerics companies are also eyeing the market and some of them have already launched their products in selected niche markets. Many licensing opportunities for fully developed generics versions of epoetin alfa are available.
Written with the senior executive needs in mind, Erythropoietin - Current Market Dynamics & Future outlook, is a must read for pharmaceutical and medical biotech professionals interested in high growth area therapeutics or in Biogenerics.
For more information visit http://www.researchandmarkets.com/reports/c9341